Abivax (ABVX) Other Non-Current Liabilities (2023 - 2026)

Abivax's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 3568.18% year-over-year to $40.1 million in Q1 2026; TTM through Mar 2026 was $40.1 million, a 3568.18% increase from a year earlier, with the FY2025 full-year figure at $37.4 million, up 2057.23% from the prior year.
• Other Non-Current Liabilities climbed to $40.1 million in Q1 2026 per ABVX's latest filing, from $37.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $40.1 million in Q1 2026 and bottomed at $29076.0 in Q2 2024.
• The 4-year median for Other Non-Current Liabilities is $1.6 million (2024), against an average of $12.6 million.
• Across the five-year window, Other Non-Current Liabilities soared 5196.93% in 2024 and soared 2084.97% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $32278.2 in 2023, then surged by 5196.93% to $1.7 million in 2024, then soared by 2084.97% to $37.4 million in 2025, then increased by 7.21% to $40.1 million in 2026.
• Per Business Quant, the three latest ABVX Other Non-Current Liabilities figures stand at $40.1 million (Q1 2026), $37.4 million (Q4 2025), and $19.4 million (Q3 2025).